Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

3.07USD
28 Mar 2017
Change (% chg)

$0.02 (+0.66%)
Prev Close
$3.05
Open
$3.07
Day's High
$3.07
Day's Low
$3.07
Volume
100
Avg. Vol
13,877
52-wk High
$6.29
52-wk Low
$2.35

Latest Key Developments (Source: Significant Developments)

Cardiome receives Notice of Compliance from Health Canada for its BRINAVESS NDS
Tuesday, 14 Mar 2017 03:02pm EDT 

Cardiome Pharma Corp : Cardiome receives notice of compliance from Health Canada for its BRINAVESS NDS .Notice of compliance enables Cardiome to begin commercializing BRINAVESS in Canada.  Full Article

Cardiome Pharma Corp says Q4 loss per share $0.18
Tuesday, 7 Mar 2017 04:00pm EST 

Cardiome Pharma Corp : Reports FY 2016 revenue $25.3 million . Cardiome reports fourth quarter and full year 2016 financial results . Q4 revenue $7.0 million versus I/B/E/S view $6.3 million . Q4 loss per share $0.18 . Reports FY 2016 revenue up 21 percent . Q4 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S .Believe Xydalba sales in 2017, followed by Trevyent launch in 2018/19 will be start of strong revenue growth for years to come.  Full Article

Cardiome announces commercial launch of Xydalba(dalbavancin) in France
Friday, 3 Mar 2017 08:00am EST 

Cardiome Pharma Corp : Cardiome Pharma Corp - received authorization from French transparency pricing commission to begin selling Xydalba in France .Cardiome Pharma Corp - it has launched Xydalba in France after receiving authorization.  Full Article

Cardiome Pharma announces commercial launch of Xydalba in Germany
Tuesday, 20 Dec 2016 08:00am EST 

Cardiome Pharma Corp : Cardiome announces commercial launch of xydalba (dalbavancin) in Germany .Cardiome Pharma - expect to follow up commercialization of xydalba in UK, german markets with launches in European countries during first half of 2017.  Full Article

Cardiome Q2 loss per share $0.37
Tuesday, 9 Aug 2016 04:00pm EDT 

Cardiome Pharma Corp : Q2 revenue $5.9 million versus i/b/e/s view $6.8 million . Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S . Cardiome reports second quarter 2016 financial results . Q2 loss per share $0.37 .Cardiome pharma corp says gross margin decreased to 71.4% and 76.1% for three and six months ended june 30, 2016, respectively.  Full Article

Cardiome prices offering of 10 mln shares at $3.00 per share
Tuesday, 26 Jul 2016 08:38am EDT 

Cardiome Pharma Corp : Says aggregate gross proceeds to company of us$30 million . Cardiome announces pricing of public offering of 10,000,000 common shares .Offering of 10 million common shares from treasury at a price to public of $3.00 per common share.  Full Article

Cardiome announces proposed public offering
Monday, 25 Jul 2016 04:01pm EDT 

Cardiome Pharma Corp : Cardiome announces proposed public offering of common shares .Says intends to use net proceeds from offering for in-licensing of dalbavancin.  Full Article

Cardiome says Esmocard and Esmocard Lyo receive pricing approval, reimbursement in Italy
Thursday, 14 Jul 2016 08:00am EDT 

Cardiome Pharma Corp : Esmocard® and Esmocard Lyo® receive pricing approval and reimbursement in Italy .Pricing approval and national reimbursement for both Esmocard(®) and Esmocard Lyo(®) (esmolol hydrochloride) was recently provided in Italy.  Full Article

Cardiome Q1 loss per share $0.06
Friday, 13 May 2016 07:07am EDT 

Cardiome Pharma Corp : Anticipate our first commercial sales of XYDALBA this year and a larger commercial roll-out during 2017 . Cardiome reports first quarter 2016 financial results . Q1 loss per share $0.06 . Q1 revenue $7.1 million versus I/B/E/S view $6.3 million .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Cardiome Pharma reports Q1 2016 financial results
Friday, 13 May 2016 07:00am EDT 

Cardiome Pharma Corp :Cardiome reports first quarter 2016 financial results.  Full Article

More From Around the Web